FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

<b>TATEMENT</b>	<b>OF CHANGES</b>	IN BENEFICIAL	<b>OWNERSHIP</b>

OMB AP	PROVAL
OMB Number:	3235-0287
Estimated averag	e burden
hours por rospons	o. 0 F

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SCHAFER GREGORY W					2. Issuer Name and Ticker or Trading Symbol ADURO BIOTECH, INC. [ ADRO ]										neck all ap Dire	onship of Reporting all applicable) Director Officer (give title		g Person(s) to Issue 10% Owne Other (spe		ner	
	,	(First) (Middle) BIOTECH, INC. 'ENUE				3. Date of Earliest Transaction (Month/Day/Year) 01/25/2018										A belo					
(Street) BERKEI	LEY C	A	94710		4.1	t Ame	ename	ndment, Date of Original Filed (Month/Day/Year)								e) <mark>X</mark> For For	<b>,</b>				
(City)	(S	tate)	(Zip)																		
1. Title of Security (Instr. 3) 2. Trans Date			saction				<u>.</u>	quired, Disposed of, or Benefic  3. Transaction Code (Instr. 8)  4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4) 5)					d (A) or	5. An Secu Bene Own	5. Amount of Securities Beneficially Owned Following Reported		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
										Code	v	Amount		A) or D)	Price	Trans	actio	tion(s) and 4)			insu. 4)
Common Stock 01/25				5/201	/2018			M		60,000 A		\$0.8	2	250,745			D				
Common Stock 01				01/25	5/201	/2018			X		3,317 A S		\$0.0	1 2	254,062			D			
		-	Гable II -								•	sed of, onvertil			-	Owne	t				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	Date,	1. Fransaction Code (Instr. 3)				Exp	6. Date Exercisa Expiration Date (Month/Day/Year			7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		s Security	8. Price Derivati Security (Instr. 5)	/e S	D. Number derivative Securities Beneficiall Dwned Following Reported Transactio Instr. 4)	Owne Form: Iy Direct or Ind (I) (Ins	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Dat Exe	te ercisable		xpiration ate	Title		Amount or Number of Shares						
Stock Option (right to buy)	\$0.82	01/25/2018			M			60,000		(1)	11	1/26/2023	Comr		60,000	\$0.00		87,322		D	
Common Stock Warrant (right to buy)	\$0.01	01/25/2018			х			3,317	09/	/30/2013	3 09	9/30/2023	Comr		3,317	\$0.00		0		D	

## **Explanation of Responses:**

1. The shares subject to the Option became fully vested and exercisable as of July 1, 2017.

## Remarks:

/s/ Jennifer Lew, Attorney-in-

**Fact** 

\*\* Signature of Reporting Person

Date

01/26/2018

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.